George Weiner, M.D.

weiner
Professor and Director, Holden Comprehensive Cancer Center
Internal Medicine
Office room number: 
5970
JPP
Office phone: 
319-353-8620
Lab room number: 
5216
MERF
Lab phone: 
319-335-7092
Research

Novel approaches to cancer immunotherapy including the evaluation of monoclonal antibody therapy, and new strategies for tumor immunization

The laboratory of Dr. George Weiner investigates new approaches to cancer immunotherapy. He also serves as the Director of the Holden Comprehensive Cancer Center and Principal Investigator of the Iowa / Mayo Lymphoma Specialized Program in Research Excellence (SPORE). His research focuses in the following areas.

Mechanisms of action of anti-tumor monoclonal antibody therapy. A number of mechanisms have been identified as contributing to the anti-tumor monoclonal antibodies. Dr. Weiner is exploring the relative role of these mechanisms of action and how they interact in vitro, in animal models and in clinical trials.

Cancer immunotherapy utilizing immunostimulatory DNA containing the CpG motif. Oligonucleotides containing the CpG motif (CpG ODN) can have potent immunostimulatory effects. Dr. Weiner is exploring novel approaches to using CpG ODN in cancer, including studies being done in collaboration with Dr. Aliasger Salem (College of Pharmacy) using CpG ODN-containing nanoparticles.

Publications: 

PubMed link

Department/Program affiliations: